|
06 May 2019 |
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare and Fatal Disease
|
|
06 May 2019 |
Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting
|
|
04 May 2019 |
Agios Announces FDA Approval of Supplemental New Drug Application (sNDA) for TIBSOVO® as Monotherapy for Newly Diagnosed Adult Patients with IDH1 Mutant Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy
|
|
03 May 2019 |
Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint
|
|
02 May 2019 |
Genkyotex Reports Clinical Evidence of Anti-fibrotic Activity by GKT831 in Liver Fibrosis Patients
|
|
02 May 2019 |
Samumed Launches Phase 3 Lorecivivint (SM04690) Clinical Program in Knee Osteoarthritis
|
|
02 May 2019 |
Exelixis Initiating Phase 3 Pivotal Trial (COSMIC-313) of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma
|
|
02 May 2019 |
Aerpio Pharmaceuticals Presents Data Showing Potential of AKB-9778, a VE-PTP Inhibitor/Tie2 Activator, to Lower Intra-ocular Pressure in Human Subjects
|
|
01 May 2019 |
3-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
|
|
01 May 2019 |
TARIS Bio Initiates New Clinical Study of TAR-302 in Overactive Bladder
|
|
01 May 2019 |
Tetra Discovery Partners Initiates Phase 2 Clinical Trial of BPN14770 in Patients with Early Alzheimer’s Disease
|
|
01 May 2019 |
Eisai buys out Purdue rights to end collaboration
|
|
01 May 2019 |
FDA approves first treatment for all genotypes of hepatitis C in pediatric patients
|
|
30 Apr 2019 |
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cancer
|
|
30 Apr 2019 |
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
|
|
30 Apr 2019 |
FDA Approves KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants with CF as Early as Six Months of Age
|
|
30 Apr 2019 |
Cerevance Achieves Key Endpoints in Phase 1 Clinical Trial of Novel Parkinson’s Disease Drug CVN424
|
|
29 Apr 2019 |
Cerecor Announces Positive Phase I Safety Data for CERC-801 in Healthy Volunteers
|
|
29 Apr 2019 |
U.S. FDA accepts New Drug Application and grants Priority Review for darolutamide
|
|
29 Apr 2019 |
OMEICOS Therapeutics Announces First-Dosing in Phase 2 Clinical Study Evaluating its Lead Program OMT-28 in Patients with Persistent Atrial Fibrillation
|
|
29 Apr 2019 |
LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion for First-Line Maintenance Treatment in BRCA-Mutated Advanced Ovarian Cancer
|
|
29 Apr 2019 |
ViiV Healthcare Submits New Drug Application to US FDA for the First Monthly, Injectable, Two-Drug Regimen of Cabotegravir and Rilpivirine for Treatment of HIV
|
|
28 Apr 2019 |
European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals’ Ondexxya™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors
|
|
28 Apr 2019 |
ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
|
|
28 Apr 2019 |
ViiV Healthcare announces CHMP Positive Opinion for Dovato® (dolutegravir/lamivudine) as a once-daily, single-pill, two-drug regimen for the treatment of HIV infection
|
